Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

(HealthDay News) — Venous thromboembolism (VTE) risk varies across hormonal contraceptives, according to a research letter published online Feb. 10 in the Journal of the American Medical Association.

HealthDay News — For infants born before 34 weeks of gestation and with a birth weight less than 1000g, probiotics used in neonatal units are associated with reduced mortality, according to a study ...

Study identifies potential treatment strategy for high-threshold peanut allergy; Emblaveo approved for complicated intra-abdominal ...

The Food and Drug Administration (FDA) has granted Fast Track designation to PP-01 (nabilone/gabapentin) for the mitigation of cannabis withdrawal ...

Use of one or more classes of medications for secondary CVD prevention peaked at 43.1 percent, decreased to 31.3 percent ...

HealthDay News — A federal judge has ordered the US Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) to restore access to public health websites that were ...

The Food and Drug Administration (FDA) has expanded the labeling for Izervay™ (avacincaptad pegol intravitreal solution) to include longer-term ...

SGLT2 inhibitors more cardioprotective in older versus younger people despite smaller reduction in HbA1c with older age ...

The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water.

The phase 2 CAFETERIA study included participants aged 4 to 14 years who were able to tolerate at least 143mg of peanut protein.

The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.